Microneedle patches (MNP) have the potential to revolutionize vaccine delivery and diagnostics. However, their laborious manufacturing process has been a major challenge until now. In a recent study published in Nature Biotechnology, researchers have developed a microneedle vaccine printer (MVP) capable of manufacturing dissolvable polymers containing stabilized mRNA vaccine. The MVP can print the microneedles in a mold, which retain the structure after being mixed with the soluble and biocompatible polymer. The MNPs have been tested on pig skin and found capable of delivering vaccines. The patches are also shelf-stable for up to six months, making them suitable for use in areas where refrigeration is problematic. The MVP could shorten the supply chain for vaccines and enable simple diagnostics that eliminate the need for blood draws, making them an ideal solution for developing regions. Previous research on MNPs has shown their efficacy in delivering rotavirus and poliovirus vaccines, and diagnostic sampling of protein biomarkers in interstitial fluid. The commercialization of MVP and MNP printers could greatly benefit global healthcare.
